Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/...

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

<article>
  <h2>FDA Approves Expanded Indication for Lilly's Jaypirca (pirtobrutinib) for CLL/SLL Treatment</h2>
  <p>Eli Lilly and Company (NYSE: LLY) has announced that the U.S. Food and Drug Administration (FDA) granted approval for Jaypirca (pirtobrutinib) to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have been previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This significant move enhances the existing label of Jaypirca and enables earlier treatment options for patients.</p>

  <section>
    <h3>Key Details Surrounding the Approval</h3>
    <p>The FDA's approval is based on findings from the BRUIN CLL-321 trial, which represents the first and only randomized Phase 3 study in CLL/SLL where all participants had previously received treatment with a covalent BTK inhibitor. This expanded indication broadens the patient demographic eligible for Jaypirca, aligning with recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.</p>
    <ul>
      <li><strong>Drug Name:</strong> Jaypirca (pirtobrutinib), available in 100 mg & 50 mg tablets.</li>
      <li><strong>Condition Treated:</strong> Relapsed or refractory CLL/SLL.</li>
      <li><strong>Type of Inhibitor:</strong> First non-covalent (reversible) BTK inhibitor approved by the FDA.</li>
    </ul>
  </section>

  <section>
    <h3>Implications of the Expanded Label</h3>
    <p>According to Dr. Jeff Sharman, Disease Chair at SCRI, "Pirtobrutinib is the only medicine in CLL or SLL studied in a randomized trial of patients previously treated with a covalent BTK inhibitor." He emphasized that Jaypirca serves as a critical option for patients who can no longer rely on traditional covalent BTK inhibitors due to disease progression or adverse effects.</p>
    <p>Jacob Van Naarden, Lilly Oncology's executive vice president, noted, "This label expansion allows physicians to use Jaypirca directly after a covalent BTK inhibitor, where we believe it has the most unique potential impact for patients." The approval also transforms the drug's prior accelerated approval into a traditional one, further solidifying its role in treatment protocols.</p>
  </section>

  <section>
    <h3>Future Directions and Clinical Trials</h3>
    <p>Currently, Lilly is conducting multiple Phase 3 studies to further investigate Jaypirca's efficacy in treating CLL/SLL. More information on these studies can be found at <a href="https://clinicaltrials.gov">clinicaltrials.gov</a>.</p>
    <p>Brian Koffman, M.D., co-founder of CLL Society, stated, "Having additional therapeutic options is critical for CLL or SLL patients following treatment with an irreversible or covalently binding BTK inhibitor." This approval ensures continuity in treatment options while preserving future therapies that target different mechanisms.</p>
  </section>

  <section>
    <h3>About Jaypirca (pirtobrutinib)</h3>
    <p>Jaypirca, previously known as LOXO-305, is a selectively designed kinase inhibitor that demonstrates a remarkable 300 times more selectivity for BTK than 98% of other tested kinases. This selective inhibition is significant for patients with B-cell malignancies, including CLL and MCL.</p>
    <p>The medication can be taken as a daily dose of 200 mg, available as either 100 mg or 50 mg tablets, with or without food, until disease progression or intolerable side effects occur.</p>
  </section>

  <section>
    <h3>Understanding CLL and SLL</h3>
    <p>Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing forms of non-Hodgkin lymphoma originating from lymphocytes, a type of white blood cell. CLL is one of the most prevalent leukemia types in adults, predicting approximately 23,690 new cases in the U.S. this year.</p>
    <p>SLL shares pathological similarities with CLL, with the primary difference being the location of cancer cells: CLL cells are found in the blood, while SLL cells reside in lymph nodes.</p>
  </section>

  <section>
    <h3>Important Safety Information</h3>
    <p>As with any medication, Jaypirca carries potential risks. Clinical trials have shown increased occurrences of serious infections and hemorrhage among users, necessitating careful patient monitoring and appropriate prophylactic measures. The prescribing information outlines these risks in detail and gives guidance for management.</p>
  </section>
</article>

Eli Lilly's Jaypirca approved for CLL/SLL patients previously treated with BTK inhibitors.
FDA approval converts Jaypirca's status to traditional from accelerated approval.
Jaypirca expands potential patient base significantly in CLL/SLL treatments.
Unique drug mechanism targets BTK pathway, enhancing treatment options for patients.
Eli Lilly continues to pursue multiple Phase 3 studies for Jaypirca.

u-s-fda-approves-expanded-indication-for-lilly-s-jaypirca-pirtobrutinib-the-first-and-only-non-covalent-reversible-btk-inhibitor-for-adults-with-relapsed-or-refractory-cll-sll-previously-treated-with-a-covalent-btk-inhibitor

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News